Celldex Therapeutics’ (CLDX) Buy Rating Reaffirmed at HC Wainwright

by · The Markets Daily

Celldex Therapeutics (NASDAQ:CLDX – Get Free Report)‘s stock had its “buy” rating reiterated by analysts at HC Wainwright in a research report issued on Friday, Benzinga reports. They currently have a $64.00 price target on the biopharmaceutical company’s stock. HC Wainwright’s price objective points to a potential upside of 96.69% from the stock’s previous close.

CLDX has been the topic of a number of other research reports. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Celldex Therapeutics in a research report on Friday, July 17th. Leerink Partners upped their price objective on Celldex Therapeutics from $70.00 to $88.00 and gave the stock an “outperform” rating in a research note on Wednesday, September 23rd. Cantor Fitzgerald increased their price objective on Celldex Therapeutics from $61.00 to $72.00 and gave the company an “overweight” rating in a report on Tuesday, September 22nd. Barclays boosted their target price on Celldex Therapeutics from $48.00 to $53.00 and gave the stock an “overweight” rating in a report on Friday, August 7th. Finally, Wall Street Zen raised Celldex Therapeutics from a “strong sell” rating to a “sell” rating in a report on Sunday, July 12th. One research analyst has rated the stock with a Strong Buy rating, eleven have issued a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $61.92.

Check Out Our Latest Stock Report on CLDX

Celldex Therapeutics Trading Up 2.8%

Shares of CLDX traded up $0.89 during trading hours on Friday, hitting $32.54. 359,417 shares of the stock traded hands, compared to its average volume of 1,060,973. Celldex Therapeutics has a 1-year low of $22.10 and a 1-year high of $45.14. The firm has a market capitalization of $2.56 billion, a PE ratio of -7.45 and a beta of 0.90. The business has a fifty day moving average of $38.38 and a 200-day moving average of $34.92.

Celldex Therapeutics (NASDAQ:CLDX – Get Free Report) last released its earnings results on Thursday, August 6th. The biopharmaceutical company reported ($0.94) earnings per share for the quarter, beating the consensus estimate of ($1.06) by $0.12. The company had revenue of $0.02 million during the quarter, compared to analyst estimates of $0.74 million. As a group, equities research analysts expect that Celldex Therapeutics will post -4.17 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Celldex Therapeutics

Institutional investors and hedge funds have recently made changes to their positions in the business. Wellington Management Group LLP boosted its holdings in Celldex Therapeutics by 11.5% in the second quarter. Wellington Management Group LLP now owns 9,543,671 shares of the biopharmaceutical company’s stock worth $355,120,000 after acquiring an additional 983,195 shares in the last quarter. Commodore Capital LP increased its position in shares of Celldex Therapeutics by 5.1% during the first quarter. Commodore Capital LP now owns 2,696,616 shares of the biopharmaceutical company’s stock valued at $85,537,000 after acquiring an additional 131,616 shares during the last quarter. Eversept Partners LP increased its position in Celldex Therapeutics by 24.6% in the first quarter. Eversept Partners LP now owns 1,788,016 shares of the biopharmaceutical company’s stock worth $56,716,000 after buying an additional 353,291 shares during the last quarter. Dimensional Fund Advisors LP increased its position in Celldex Therapeutics by 62.6% in the first quarter. Dimensional Fund Advisors LP now owns 1,059,534 shares of the biopharmaceutical company’s stock worth $33,596,000 after buying an additional 407,818 shares during the last quarter. Finally, Assenagon Asset Management S.A. increased its position in Celldex Therapeutics by 438.3% in the second quarter. Assenagon Asset Management S.A. now owns 788,696 shares of the biopharmaceutical company’s stock worth $29,347,000 after buying an additional 642,171 shares during the last quarter.

Celldex Therapeutics Company Profile

(Get Free Report)

Celldex Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on developing antibody-based therapies for diseases with significant unmet medical needs. The company’s research programs target mast cell–mediated disorders, inflammatory diseases, and cancer, using engineered antibodies designed to modulate specific immune-system pathways.

Celldex’s lead product candidate is barzolvolimab, an investigational monoclonal antibody that targets the KIT receptor on mast cells.

See Also